Otsuka Holdings Co Ltd represents values such as innovation, creativity, and contributing to the betterment of society. As a global pharmaceutical company, they aim to improve the health and well-being of people around the world. Otsuka's corporate philosophy revolves around the concept of "Otsuka-people creating new products for better health worldwide," reflecting their commitment to developing cutting-edge medicines and healthcare solutions. With a focus on patient-centricity and social responsibility, Otsuka Holdings Co Ltd strives to address unmet medical needs and make a positive impact on society through their products and services.

Otsuka Holdings Co Ltd is primarily present in various countries and regions across the globe. The company has a significant presence in Japan, where it originated and is headquartered. In addition to its strong domestic presence, Otsuka Holdings Co Ltd has expanded its operations internationally. It has established a notable presence in the United States, Europe, and Asia, including key markets such as the United Kingdom, Germany, China, and South Korea. Through its global network, Otsuka Holdings Co Ltd aims to provide its products and services to a diverse range of customers worldwide, contributing to its growth and success as a multinational corporation.

Otsuka Holdings Co Ltd has achieved remarkable milestones throughout its history. Notably, the company experienced substantial growth, expanding its global presence and building a strong reputation in the pharmaceutical and healthcare industries. Otsuka Holdings Co Ltd successfully introduced innovative medical products and treatments, revolutionizing patient care and improving quality of life. Additionally, the company has fostered strategic partnerships, enabling the exchange of knowledge and collaboration on cutting-edge research initiatives. Otsuka Holdings Co Ltd's dedication to technological advancements, commitment to patient-centric care, and continuous efforts in medical breakthroughs have contributed to its extraordinary achievements in the industry.

Otsuka Holdings Co Ltd is a Japanese pharmaceutical company that was founded in 1964. It is headquartered in Tokyo and operates globally. Otsuka Holdings has a rich history and has been dedicated to improving the health and well-being of people worldwide. The company specializes in the research, development, and manufacturing of innovative pharmaceutical products, as well as providing comprehensive healthcare solutions. Otsuka Holdings is known for its commitment to mental health, and its flagship product, Abilify, has been widely used for the treatment of schizophrenia and bipolar disorder. With a strong emphasis on innovation and patient-centric care, Otsuka Holdings continues to make significant contributions to the healthcare industry.

The main competitors of Otsuka Holdings Co Ltd in the market are major pharmaceutical companies such as Pfizer, Novartis, and GlaxoSmithKline. These global competitors also operate within the healthcare industry and offer a wide range of products and services similar to Otsuka Holdings. Despite facing stiff competition in the market, Otsuka Holdings continues to thrive through its innovative research and development efforts, diversification of product portfolio, and strategic collaborations. Otsuka Holdings remains firmly focused on its commitment to improving the health and well-being of people through its various subsidiaries and business segments.

Otsuka Holdings Co Ltd is primarily active in the healthcare and pharmaceutical industries.

The business model of Otsuka Holdings Co Ltd focuses on healthcare, pharmaceuticals, and nutraceuticals. As a leading global company, Otsuka Holdings creates and markets innovative products and solutions to improve the overall health and well-being of individuals worldwide. Their business strategy centers around research, development, and commercialization of pharmaceuticals and medical devices that target unmet medical needs. In addition, Otsuka Holdings also offers nutritional food products and beverages. By leveraging their expertise and commitment to innovation, Otsuka Holdings aims to contribute to the advancement of healthcare and ultimately improve the quality of life for people around the globe.

Otsuka Holdings Co의 P/E 비율은 16.77입니다.

Otsuka Holdings Co의 P/S 비율은 1.82입니다.

Otsuka Holdings Co에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 Otsuka Holdings Co 매출은 2.22 바이오. JPY입니다.

예상되는 Otsuka Holdings Co 이익은 240.69 조. JPY입니다.

Otsuka Holdings Co Ltd is an internationally active company that operates in various business sectors. Their business model is based on offering innovative products and services that aim to improve people's lives. The company operates in four business sectors: Pharma, Nutraceuticals, Medical Devices, and others (including Contract Manufacturing and Real Estate). In the Pharma sector, Otsuka Holdings produces and distributes pharmaceuticals for a variety of applications. These include products for the treatment of psychiatric disorders, kidney diseases, cardiovascular diseases, and other illnesses. Well-known brands include Abilify® and Samsca®. Another important business sector of Otsuka Holdings is Nutraceuticals. The company offers a wide range of nutritional supplements and functional foods based on scientific principles. Many of these products aim to improve consumers' well-being and health. Examples include Collagen C®, a new generation of beauty and anti-aging products, and Soyjoy®, a brand of energy-rich snacks based on soy. In the field of medical technology, Otsuka Holdings develops and produces a variety of medical devices to improve clinical outcomes and enhance quality of life. The focus here is on stroke treatment and hemodialysis. The products range from neurosonography to blood purification systems. In addition to these three core business sectors, Otsuka Holdings is also active in other areas. The company offers contract manufacturing services to support other companies in the production of pharmaceuticals, cosmetics, and foods. Otsuka Holdings also has a significant real estate division that focuses on property development and management investments. Overall, Otsuka Holdings is a global company that offers its customers a wide range of innovative and high-quality products and services. The company's goal is to improve people's lives worldwide and contribute to sustainable growth. To increase market presence and strengthen customer relationships, Otsuka Holdings has also entered into various distribution partnerships with other companies. Together with partners such as Bristol Myers Squibb and Takeda Pharmaceutical, the company focuses on developing new products and technologies to provide the best to customers worldwide. In summary, Otsuka Holdings Co Ltd offers a wide range of products and services in various business sectors, from Nutraceuticals to medical devices. The company strives to improve people's lives and relies on innovation and high-quality products. With strong partnerships and a global network, the company positions itself as a key player in the global healthcare industry.

Otsuka Holdings Co은(는) 연간 번의 배당을 통해 100 JPY의 배당금을 지급합니다.

Otsuka Holdings Co의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Otsuka Holdings Co의 ISIN은 JP3188220002입니다.

Otsuka Holdings Co의 WKN은 A1C9KC입니다.

Otsuka Holdings Co의 티커는 4578.T입니다.

지난 12개월 동안 Otsuka Holdings Co은(는) 110 JPY 의 배당금을 지급했습니다. 이는 약 1.48 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Otsuka Holdings Co은(는) 113.93 JPY의 배당금을 지급할 것으로 예상됩니다.

Otsuka Holdings Co의 현재 배당 수익률은 1.48 %입니다.

Otsuka Holdings Co은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Otsuka Holdings Co은(는) 지난 16년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 113.93 JPY의 배당금이 예상됩니다. 이는 배당수익률 1.53 %에 해당합니다.

Otsuka Holdings Co은 '건강' 섹터에 속합니다.

Otsuka Holdings Co의 마지막 배당금을 60 JPY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Otsuka Holdings Co는 100 JPY를 배당금으로 지급했습니다.

Otsuka Holdings Co의 배당금은 JPY에 지급됩니다.